After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, AKRO falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Akero Therapeutics Inc is $4.37B. A total of 1.44 million shares were traded on the day, compared to an average of 2.06M shares.
In the most recent transaction, Cheng Andrew sold 30,000 shares of AKRO for 53.98 per share on Oct 10 ’25. After the transaction, the President and CEO now owns 526,114 company shares. In a previous transaction on Oct 07 ’25, Rolph Timothy sold 12,500 shares at 46.08 per share. AKRO shares that Chief Scientific Officer owns now total 166,571.
Among the insiders who bought shares, Timothy Rolph acquired of 56,369 shares on Oct 07 ’25 at a per-share price of $46.04. In another insider transaction, Young Jonathan sold 12,500 shares at $47.76 per share on Oct 01 ’25. Company shares held by the Chief Operating Officer now total 196,898.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, AKRO has a high of $58.40 and a low of $21.34.
As of this writing, AKRO has an earnings estimate of -$0.93 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of -$0.89 per share and a lower estimate of -$1.0. The company reported an EPS of -$1.05 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $12.84, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 3.83.
